Oral Contraception Into the 1990sH. W. Halbe, H. Rekers |
Contents
List of principal contributors | 7 |
vitro and in vivo pharmacological tests | 21 |
The effects of oral contraceptives and postmenopausal | 31 |
Copyright | |
6 other sections not shown
Common terms and phrases
3-ketodesogestrel 30 µg ethinylestradiol adverse effects androgen receptor androgenic activity associated benefits binding studies breast cancer C-peptide carbohydrate cardiovascular disease changes Clin clinical combined oral contraceptives contraceptive progestins coronary artery disease coronary heart disease cycle control desogestrel dinor DSG group effect of oral Engl epidemiological estrogen estrogen dose ethinylestradiol excretion fertile Figure gestodene glucose Gynecol gynecological HDL cholesterol HDL cholesterol concentrations increase insulin irregular bleeding Kloosterboer Knopp Lancet LDL-C levels levonorgestrel lipoprotein lipids LNG group Marvelon menopause Mercilon metabolites mg/dl Microgynon minimal mortality myocardial infarction niacin norethisterone Obstet OGTT oral contraceptive formulations oral contraceptive users oral contraceptives containing ovarian ovulation pill plasma postmenopausal estrogen pregnancy progestational progesterone receptor progestins progestogen prostacyclin prostanoids rats receptor binding reduction in coronary sex hormone sex steroid SHBG side-effects steroid hormones Table tablets therapy thrombosis thromboxane triglyceride urinary vascular disease VLDL withdrawal bleeding women taking Ylikorkala